Page 1 | Search Results | Blood Advances | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding

Maureane Hoffman

Blood Adv (2021) 5 (18): 3736.

https://doi.org/10.1182/bloodadvances.2021004802

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers

Genmin Lu, Pamela B. Conley, Janet M. Leeds, Mark J. Karbarz, Gallia G. Levy, Vandana S. Mathur, Janice Castillo, Mark Crowther, John T. Curnutte

Blood Adv (2020) 4 (4): 728–739.

https://doi.org/10.1182/bloodadvances.2019000885

Published: 2020

Includes: Supplemental data

Journal Articles

Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy

Hanny Al-Samkari, Jean M. Connors

Blood Adv (2019) 3 (22): 3770–3779.

https://doi.org/10.1182/bloodadvances.2019000369

Published: 2019

Journal Articles

American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy

Shannon M. Bates, Anita Rajasekhar, Saskia Middeldorp, Claire McLintock, Marc A. Rodger, Andra H. James, Sara R. Vazquez, Ian A. Greer, John J. Riva, Meha Bhatt, Nicole Schwab, Danielle Barrett, Andrea LaHaye, Bram Rochwerg

Blood Adv (2018) 2 (22): 3317–3359.

https://doi.org/10.1182/bloodadvances.2018024802

Published: 2018

Includes: Supplemental data

Journal Articles

Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Marc Alan Rodger, Gregoire Le Gal

Blood Adv (2018) 2 (21): 3081–3087.

https://doi.org/10.1182/bloodadvances.2018020230

Published: 2018

Journal Articles

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors

Manu T. Kalathottukaren, A. Louise Creagh, Srinivas Abbina, Genmin Lu, Mark J. Karbarz, Anjali Pandey, Pamela B. Conley, Jayachandran N. Kizhakkedathu, Charles Haynes

Blood Adv (2018) 2 (16): 2104–2114.

https://doi.org/10.1182/bloodadvances.2016003616

Published: 2018

Includes: Supplemental data

Journal Articles

The use of defibrotide in blood and marrow transplantation

Paul G. Richardson, Enric Carreras, Massimo Iacobelli, Bijan Nejadnik

Blood Adv (2018) 2 (12): 1495–1509.

https://doi.org/10.1182/bloodadvances.2017008375

Published: 2018

Journal Articles

Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin

Romy M. W. Kremers, Stéphane Zuily, Hilde Kelchtermans, Tessa C. Peters, Saartje Bloemen, Véronique Regnault, H. Coenraad Hemker, Philip G. de Groot, Denis Wahl, Bas de Laat

Blood Adv (2018) 2 (11): 1315–1324.

https://doi.org/10.1182/bloodadvances.2018018036

Published: 2018

Includes: Supplemental data

Journal Articles

2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia

Elizabeth Tkaczynski, Abinaya Arulselvan, John Tkaczynski, Stephen Avery, Liqing Xiao, Beverly Torok-Storb, Kraig Abrams, Narayanam V. Rao, Gregory Johnson, Thomas P. Kennedy, Mortimer Poncz, Michele P. Lambert

Blood Adv (2018) 2 (7): 754–761.

https://doi.org/10.1182/bloodadvances.2017013672

Published: 2018

Includes: Supplemental data

Journal Articles

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia

Tibor J. Kovacsovics, Alice Mims, Mohamed E. Salama, Jeremy Pantin, Narayanam Rao, Ken M. Kosak, Peter Ahorukomeye, Martha J. Glenn, Michael W. N. Deininger, Kenneth M. Boucher, Linda M. Bavisotto, Gerardo Gutierrez-Sanchez, Thomas P. Kennedy, Stephen G. Marcus, Paul J. Shami

Blood Adv (2018) 2 (4): 381–389.

https://doi.org/10.1182/bloodadvances.2017013391

Published: 2018

Journal Articles

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Surbhi Shah, Faye L. Norby, Yvonne H. Datta, Pamela L. Lutsey, Richard F. MacLehose, Lin Y. Chen, Alvaro Alonso

Blood Adv (2018) 2 (3): 200–209.

https://doi.org/10.1182/bloodadvances.2017010694

Published: 2018

Includes: Supplemental data

Journal Articles

Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants

Jordan K. Schaefer, Suman L. Sood, Brian Haymart, Xiaokui Gu, Xiaowen Kong, Eva Kline-Rogers, Steven Almany, Jay Kozlowski, Gregory D. Krol, Scott Kaatz, James B. Froehlich, Geoffrey D. Barnes

Blood Adv (2017) 1 (26): 2536–2540.

https://doi.org/10.1182/bloodadvances.2017012377

Published: 2017

Journal Articles

Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy

William G. Jackson, Clara Oromendia, Ozan Unlu, Doruk Erkan, Maria T. DeSancho

Blood Adv (2017) 1 (25): 2320–2324.

https://doi.org/10.1182/bloodadvances.2017008185

Published: 2017

Journal Articles

Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S

José A. Fernández, Xiao Xu, Ranjeet K. Sinha, Laurent O. Mosnier, Michel F. Sanner, John H. Griffin

Blood Adv (2017) 1 (18): 1423–1426.

https://doi.org/10.1182/bloodadvances.2017007005

Published: 2017

Includes: Supplemental data

Journal Articles

Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins

Amy K. L. Chui, Tilini N. Gunatillake, Vera Ignjatovic, Paul T. Monagle, Padma Murthi, Shaun P. Brennecke, John M. Whitelock, Joanne M. Said

Blood Adv (2017) 1 (16): 1243–1253.

https://doi.org/10.1182/bloodadvances.2017004333

Published: 2017

Journal Articles

Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis-associated cancer

Yassene Mohammed, Bart J. van Vlijmen, Juncong Yang, Andrew J. Percy, Magnus Palmblad, Christoph H. Borchers, Frits R. Rosendaal

Blood Adv (2017) 1 (15): 1080–1087.

https://doi.org/10.1182/bloodadvances.2017007955

Published: 2017

Includes: Supplemental data

NARROW

Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding

A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers

Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy

American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy

Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors

The use of defibrotide in blood and marrow transplantation

Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin

2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation

Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants

Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy

Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S

Antiangiogenic effects of decorin restored by unfractionated, low molecular weight, and nonanticoagulant heparins

Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis-associated cancer

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only